Raymond Taeyong Chung, M.D.
This page shows the publications co-authored by Raymond Chung and Darrick Li.
Li DK, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. Methods Mol Biol. 2019; 1911:3-32.
Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken). 2017 Dec; 10(6):148-151.
Li DK, Chung RT. Reply to antiviral therapy and hepatocellular carcinogenesis. Cancer. 2016 Jan 01; 122(1):158.
Li DK, Chung RT. Reply to direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution? Cancer. 2015 Dec 01; 121(23):4269-70.
Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015 Sep 01; 121(17):2874-82.
Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res. 2019; 5.
Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2018 06; 67(6):2244-2253.
Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K. Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS One. 2019; 14(5):e0217442.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.